Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer

A Musolino; N Naldi; M V Dieci; D Zanoni; A Rimanti; D Boggiani; P Sgargi; D G Generali; F Piacentini; M Ambroggi; K Cagossi; L Gianni; S Sarti; G Bisagni; A Ardizzoni; P F Conte; V Guarneri

doi:10.1038/tpj.2016.51

journal article Jul 05, 2016

Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer

A Musolino N Naldi M V Dieci D Zanoni A Rimanti D Boggiani P Sgargi D G Generali F Piacentini M Ambroggi K Cagossi L Gianni S Sarti G Bisagni A Ardizzoni P F Conte V Guarneri

The Pharmacogenomics Journal Vol. 16 No. 5 pp. 472-477 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/tpj.2016.51

Topics

No keywords indexed for this article. Browse by subject →

References

46

[1]

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogene

Dennis J. Slamon, Gary M. Clark, Steven G. Wong et al.

Science 1987 10.1126/science.3798106

[2]

Musolino A, Boggiani D, Sikokis A, Rimanti A, Pellegrino B, Vattiato R et al. Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers. Cancer Treat Rev 2016; 43: 1–7. 10.1016/j.ctrv.2015.11.010

[3]

Slamon DJ, Eiermann W, Robert NJ, Giermek J, Martin M, Jasiowka M et al. Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer. Cancer Res 2015; 75 (Suppl 24): 5169 (abstract S5-04).

[4]

Lavaud P, Andre F . Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. BMC Med 2014; 12: 132. 10.1186/s12916-014-0132-3

[5]

Montemurro F, Scaltriti M . Biomarkers of drugs targeting HER-family signalling in cancer. J Pathol 2014; 232: 219–229. 10.1002/path.4269

[6]

Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL . Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002; 62: 4132–4141.

[7]

Lu Y, Zi X, Zhao Y, Pollak M . Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells. Biochem Biophys Res Commun 2004; 313: 709–715. 10.1016/j.bbrc.2003.12.007

[8]

Dubská L, Andera L, Sheard MA . HER2 signaling downregulation by Trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAIL-induced apoptosis. FEBS Lett 2005; 579: 4149–4158. 10.1016/j.febslet.2005.06.047

[9]

Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of Trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26: 1789–1796. 10.1200/jco.2007.14.8957

[10]

Yang W, Klos K, Yang Y, Smith TL, Shi D, Yu D . ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer 2002; 94: 2855–2861. 10.1002/cncr.10553

[11]

Baselga J, Cortés J, Im SA, Clark E, Ross G, Kiermaier A et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol 2014; 32: 3753–3761. 10.1200/jco.2013.54.5384

[12]

Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates Trastuzumab-dependent cell cytotoxicity. Oncogene 2009; 28: 803–814. 10.1038/onc.2008.432

[13]

Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006; 94: 259–267. 10.1038/sj.bjc.6602930

[14]

Biology and clinical relevance of human natural killer cells

MJ Robertson, J Ritz

Blood 1990 10.1182/blood.v76.12.2421.2421

[15]

Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M . Fc-gamma-RIIIa-158 V/F polymorphism influences the binding of IgG by natural killer cell Fc-gamma-RIIIa, independently of the Fc-gamma-RIIIa-48 L/R/H phenotype. Blood 1997; 90: 1109–1114. 10.1182/blood.v90.3.1109

[16]

Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improves binding to the Fc gamma R. J. Biol Chem 2001; 9: 6591–6604. 10.1074/jbc.m009483200

[17]

Negri FV, Musolino A, Naldi N, Bortesi B, Missale G, Laccabue D et al. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependent cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. Pharmacogenomics J 2014; 14: 14–19. 10.1038/tpj.2012.54

[18]

Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K et al. FcgammaR2A and 3 A polymorphisms predict clinical outcome of Trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol 2011; 22: 1302–1307. 10.1093/annonc/mdq585

[19]

Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S et al. Analysis of Fcgamma receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res 2012; 18: 3478–3486. 10.1158/1078-0432.ccr-11-2294

[20]

Norton N, Olson RM, Pegram M, Tenner K, Ballman KV, Clynes R et al. Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831. Cancer Immunol Res 2014; 2: 962–969. 10.1158/2326-6066.cir-14-0059

[21]

Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C et al. Lapatinib with Trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2012; 379: 633–640. 10.1016/s0140-6736(11)61847-3

[22]

Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S et al. Pre-operative chemotherapy plus Trastuzumab, Lapatinib, or both in Epidermal Growth Factor 2-positive operable breast cancer: results of the randomized phase II study CHER-LOB. J Clin Oncol 2012; 30: 1989–1995. 10.1200/jco.2011.39.0823

[23]

Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol 2014; 25: 611–618. 10.1093/annonc/mdt556

[24]

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILsWorking Group 2014. Ann Oncol 2015; 26: 259–271. 10.1093/annonc/mdu450

[25]

Dieci MV, Bisagni G, Cagossi K, Bottini A, Sarti S, Piacentini F et al. Tumor infiltrating lymphocytes and correlation with outcome in the Cher-LOB study. Cancer Res 2015; 75 (Suppl 24): 5170 (abstract PD1-1).

[26]

Chernoff H, Lehmann EL . The use of maximum likelihood estimates in χ2 tests for goodness-of-fit. Ann Math Stat 1954; 25: 579–586. 10.1214/aoms/1177728726

[27]

Freeman DH Applied Categorical Data Analysis. Marcel Dekker, Inc.: New York, NY, USA, 1987.

[28]

Hardy GH . Mendelian proportions in a mixed population. Science 1908; 28: 49–50. 10.1126/science.28.706.49

[29]

Nonparametric Estimation from Incomplete Observations

E. L. Kaplan, Paul Meier

Journal of the American Statistical Association 1958 10.1080/01621459.1958.10501452

[30]

Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170.

[31]

Regression Models and Life-Tables

D. R. Cox

Journal of the Royal Statistical Society Series B:... 1972 10.1111/j.2517-6161.1972.tb00899.x

[32]

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

Sandra M. Swain, Jose Baselga, Sung-Bae Kim et al.

New England Journal of Medicine 2015 10.1056/nejmoa1413513

[33]

Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 2012; 30: 2585–2592. 10.1200/jco.2011.35.6725

[34]

Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25–32. 10.1016/s1470-2045(11)70336-9

[35]

Piccart-Gebhart MJ, Holmes AP, Baselga J, De Azambuja E, Dueck AC, Viale G et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2–positive breast cancer: results from the randomized phase iii adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol 2015; 34: 1034–1042. 10.1200/jco.2015.62.1797

[36]

US National Institutes of Health: a study of Pertuzumab in Addition to Chemotherapy and Herceptin (trastuzumab) As Adjuvant Therapy in Patients with HER2-Positive Primary Breast Cancer. Available at https://clinicaltrials.gov/show/NCT01358877. Accessed 18 January 2016.

[37]

US National Institutes of Health: a study of Kadcyla (trastuzumab emtansine) Plus Perjeta (pertuzumab) Following Anthracyclines in Comparison with Herceptin (trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines As Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer. Available at https://clinicaltrials.gov/show/NCT01966471. Accessed 18 January 2016.

[38]

Perez EA, Romond EH, Suman VJ, Jeong J-H, Davidson NE, Geyer CE et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-postive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29: 3366–3373. 10.1200/jco.2011.35.0868

[39]

Guarneri V, Dieci MV, Frassoldati A, Maiorana A, Ficarra G, Bettelli S et al. Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual Anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer. Oncologist 2015; 20: 1001–1010. 10.1634/theoncologist.2015-0138

[40]

Lejeune J, Thibault G, Ternant D, Cartron G, Watier H, Ohresser M . Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies. J Clin Oncol 2008; 26: 5489–5491. 10.1200/jco.2008.19.4118

[41]

Salgado R, Denkert C, Campbell C, Savas P, Nucifero P, Aura C et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol 2015; 1: 448–454. 10.1001/jamaoncol.2015.0830

[42]

Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2–positive and triple-negative primary breast cancers. J Clin Oncol 2015; 33: 983–991. 10.1200/jco.2014.58.1967

[43]

Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2

Eric F. Zhu, Shuning A. Gai, Cary F. Opel et al.

Cancer Cell 2015 10.1016/j.ccell.2015.03.004

[44]

Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR et al. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the north central cancer treatment group n9831 adjuvant trastuzumab trial. J Clin Oncol 2015; 33: 701–708. 10.1200/jco.2014.57.6298

[45]

Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Agbor-Tarh D, Campbell C et al. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clin Cancer Res 2015; 21: 569–576. 10.1158/1078-0432.ccr-14-1824

[46]

Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells In vitro and controls tumor expansion in vivo via low-affinity activating fc receptors. Cancer Res 2007; 67: 8882–8890. 10.1158/0008-5472.can-07-0696

Cited By

22

Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

Hope S. Rugo, Seock-Ah Im · 2023

Journal of Clinical Oncology

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer

Hope S. Rugo, Seock-Ah Im · 2021

JAMA Oncology

Metrics

22

Citations

46

References

Details

Published: Jul 05, 2016
Vol/Issue: 16(5)
Pages: 472-477
License: View

Authors

Dipartimento di Fisica, Università La Sapienza , P.le A. Moro 2, I-00185 Roma , Italy; INFN Sezione di Roma , P.le A. Moro 2, I-00185 Roma , Italy

Cite This Article

A Musolino, N Naldi, M V Dieci, et al. (2016). Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer. The Pharmacogenomics Journal, 16(5), 472-477. https://doi.org/10.1038/tpj.2016.51

Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer

You May Also Like